Kangrui Biological

Kangrui Biological was established in Guangzhou in October 2012. Currently, one of its Class 1 new drug pipelines is about to complete Phase I clinical trials in both China and the United States, and is conducting multiple IIT studies for various indications in China. It is expected to initiate Phase II clinical trials for two different indications in both China and the U.S. by the end of the year. This new drug has the potential to become the world’s first eye drop treatment for ocular neovascular diseases. Another new drug pipeline for the prevention and treatment of cataracts has entered the preclinical development stage, with plans to submit an IND application for clinical trials by the end of the year.